Hidden lung damage common in immune deficiency patients

NCT ID NCT06355323

Knowledge-focused Sponsor: CHU de Reims Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study in France looked at how common bronchiectasis (permanent lung damage) is in 46 adults with primary humoral immunodeficiency, a condition that weakens the immune system. Participants had a chest CT scan and lung function tests to check for bronchiectasis. The goal was to find out how often it occurs and if there are ways to predict it, since early detection could prevent serious breathing problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better predict and detect bronchiectasis early in patients with primary humoral immunodeficiency.
What could go wrong: This is a small, completed observational study with only 46 participants, so results may not apply to broader populations. It does not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

46 people

The number who actually took part.

Started

Nov 2022

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

inclusion criteria : * Patients with primary humoral immunodeficiency defined as following : * Common variable immunodeficiency : Marked decreased in IgG seric concentration \< 5 g/L and in IgA seric concentration or IgM seric concentration (-2SD), without secondary cause * IgG subclass deficiency : marked decrease (-2SD) in at least one IgG subclass (IgG1, 2, 3 et 4) with or without IgA or IgM deficiency * Selective IgM Deficiency : isolated decrease un IgM seric concentration \<0.3g/L, without IgG or IgA deficiency * Adult patients * Patients with or without previously identified pulmonary complications * Patients agreeing to participate to the study * Patients insured under the French social security system Non-inclusion criteria : * Patients\< 18 years of age * Patients protected by law * Patients for whom CT scan is not feasible (claustrophobia, obesity…) * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Common variable immunodeficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

common variable immunodeficiency inborn error of immunity Primary Immunodeficiency Diseases selective IgG immunodeficiency selective IgG subclass deficiency selective IgM deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Common variable immunodeficiency IgG subclass deficiency Primary immunodeficiency Selective IgM deficiency

Hidden lung damage common in immune deficiency patients

What the study statuses mean